quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:04:39·57d
SECFiling
Akebia Therapeutics Inc. logo

Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

AKBA· Akebia Therapeutics Inc.
Health Care
Original source

Companies

  • AKBA
    Akebia Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jun 4UpdateH.C. Wainwright$8.00
  • Apr 28UpdateLeerink Partners$7.00
  • Apr 1UpdateJefferies$6.00
  • Nov 29UpdateBTIG Research$4.00
  • Aug 28UpdateH.C. Wainwright$3.75
  • May 31UpdatePiper Sandler$4.00

Related

  • SEC8d
    SEC Form PRE 14A filed by Akebia Therapeutics Inc.
  • PR11d
    Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
  • PR17d
    Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
  • INSIDER20d
    SEC Form 4 filed by Vickers Philip J.
  • INSIDER20d
    SEC Form 3 filed by new insider Vickers Philip J.
  • PR21d
    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC22d
    Akebia Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
  • PR22d
    Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022